litlas
Log inCreate account

Nicolás Meyer

Active 2003–2026

Also published as
Nicolas Meyer
125
Papers
18,423
Citations
63
h-index
115
i10-index

Citations

Citations per year for Nicolás Meyer1976: 1 citations1995: 1 citations1997: 2 citations2002: 1 citations2003: 2 citations2004: 5 citations2005: 1 citations2006: 4 citations2007: 10 citations2008: 12 citations2009: 21 citations2010: 17 citations2011: 27 citations2012: 48 citations2013: 61 citations2014: 56 citations2015: 105 citations2016: 209 citations2017: 297 citations2018: 340 citations2019: 846 citations2020: 1,030 citations2021: 1,057 citations2022: 794 citations2023: 579 citations2024: 823 citations2025: 349 citations2026: 13 citations1977–1994: no citations, so these years are not shown1996: no citations, so this year is not shown1998–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,497 citing papers, 24.1% of this breakdownChina: 810 citing papers, 7.8% of this breakdownFrance: 699 citing papers, 6.7% of this breakdownItaly: 659 citing papers, 6.3% of this breakdownGermany: 628 citing papers, 6.1% of this breakdownUnited Kingdom: 605 citing papers, 5.8% of this breakdownAustralia: 470 citing papers, 4.5% of this breakdownSpain: 361 citing papers, 3.5% of this breakdownCanada: 340 citing papers, 3.3% of this breakdownNetherlands: 339 citing papers, 3.3% of this breakdownSwitzerland: 269 citing papers, 2.6% of this breakdownJapan: 269 citing papers, 2.6% of this breakdown
0%24.1%Other 23.4%

Institutions

Fields

  • Medicine74.8%
  • Biochemistry, Genetics and Molecular Biology13.7%
  • Immunology and Microbiology6.8%
  • Engineering1%
  • Computer Science1%
  • Neuroscience0.9%
  • Other1.8%

Topics

  • Cancer Immunotherapy and Biomarkers13.7%
  • Immunotherapy and Immune Responses5.5%
  • CAR-T cell therapy research5.1%
  • Cutaneous Melanoma Detection and Management4.3%
  • Melanoma and MAPK Pathways4.1%
  • Immune Cell Function and Interaction2.5%
  • Other64.8%

Coauthors

All papers

Open in search
  1. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Authors: Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto - New England Journal of Medicine 2017 cited by 2,207

  2. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

    Authors: Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Linda M. Rollin, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok, F. Stephen Hodi - New England Journal of Medicine 2015 cited by 2,763

  3. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

    Authors: Michael A. Davies, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Keith T. Flaherty, Ana Arance, Vanna Chiarion‐Sileni, L. Thomas, Thierry Lesimple, Laurent Mortier, Stergios J. Moschos, David Hogg, Iván Márquez‐Rodas, Michele Del Vecchio, Célèste Lebbé, Nicolás Meyer, Ying Zhang, Yingjie Huang, Bijoyesh Mookerjee, Georgina V. Long - The Lancet Oncology 2017 cited by 775

  4. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    Authors: F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Christine E. Horak, Paul Gagnier, Joel Jiang, Jedd D. Wolchok, Michael A. Postow - The Lancet Oncology 2016 cited by 980

  5. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

    Authors: Célèste Lebbé, Nicolás Meyer, Laurent Mortier, Iván Márquez‐Rodas, Caroline Robert, Piotr Rutkowski, Alexander M. Menzies, Thomas Eigentler, Paolo A. Ascierto, Michael Smylie, Dirk Schadendorf, Mazhar Ajaz, Inge Marie Svane, René González, Linda Rollin, Jennifer Lord‐Bessen, Abdel Saci, E. Grigoryeva, Jacopo Pigozzo - Journal of Clinical Oncology 2019 cited by 398

  6. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

    Authors: Florie Bertrand, Anne Montfort, Elie Marcheteau, Caroline Imbert, Julia Gilhodes, Thomas Filleron, Philippe Rochaix, Nathalie Andrieu‐Abadie, Thierry Levade, Nicolás Meyer, Céline Colacios, Bruno Ségui - Nature Communications 2017 cited by 367

  7. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

    Authors: Jean‐Jacques Grob, René González, Nicole Basset‐Séguin, Olga Vornicova, Jacob Schachter, Abhishek Joshi, Nicolás Meyer, Florent Grange, Josep M. Piulats, Jessica R. Bauman, Pingye Zhang, Burak Gümüşçü, Ramona F. Swaby, Brett Hughes - Journal of Clinical Oncology 2020 cited by 289

  8. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600–Mutant Unresectable or Metastatic Melanoma

    Authors: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - Journal of Clinical Oncology 2022 cited by 163

  9. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

    Authors: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul Nathan, Piotr Rutkowski, О. В. Леонов, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean‐Jacques Grob, Nicolás Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steve Green, T Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - 2022 cited by 146

  10. The TNF Paradox in Cancer Progression and Immunotherapy

    Authors: Anne Montfort, Céline Colacios, Thierry Levade, Nathalie Andrieu‐Abadie, Nicolás Meyer, Bruno Ségui - Frontiers in Immunology 2019 cited by 303

  11. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

    Authors: Myriam Delaunay, J. Cadranel, Amélie Lusque, Nicolás Meyer, V. Gounant, Denis Moro‐Sibilot, Jean‐Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Métivier, Pascale Tomasini, Éric Dansin, M. Pérol, M. Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, S. Couraud, Stéphane Dalle, M.‐T. Leccia, M. Jaffro, S. Collot, Grégoire Prévôt, Julie Milia, Julien Mazières - European Respiratory Journal 2017 cited by 421

  12. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

    Authors: Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolás Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz‐Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean‐Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz‐Merino, André van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Öcek Baş, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina V. Long - Journal of Clinical Oncology 2022 cited by 162

  13. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

    Authors: Brett Hughes, E. Munoz-Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, B. Gumuscu, Ramona F. Swaby, Jean‐Jacques Grob - Annals of Oncology 2021 cited by 200

  14. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

    Authors: Anne Montfort, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhès, Cécile Pagès, Pascale Olivier, Maha Ayyoub, Muriel Mounier, Amélie Lusque, Stéphanie Brayer, Jean‐Pierre Delord, Nathalie Andrieu‐Abadie, Thierry Levade, Céline Colacios, Bruno Ségui, Nicolás Meyer - Clinical Cancer Research 2020 cited by 102

  15. Incidence and prevalence of inflammatory myopathies: a systematic review

    Authors: Alain Meyer, Nicolás Meyer, Mickaël Schaeffer, Jacques‐Eric Gottenberg, Bernard Gény, Jean Sibilia - Lara D. Veeken 2014 cited by 369

  16. Evolutionary design of explainable algorithms for biomedical image segmentation

    Authors: Kévin Cortacero, Brienne McKenzie, Sabina Müller, Roxana Khazen, Fanny Lafouresse, Gaëlle Corsaut, Nathalie Van Acker, François-Xavier Frénois, Laurence Lamant, Nicolas Meyer, B. Vergier, Dennis G. Wilson, Hervé Luga, Oskar Staufer, Michael L. Dustin, Salvatore Valitutti, Sylvain Cussat‐Blanc - Nature Communications 2023 cited by 42

  17. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

    Authors: Nicole Basset‐Séguin, Axel Hauschild, Rainer Kunstfeld, Jean‐Jacques Grob, Brigitte Dréno, Laurent Mortier, Paolo A. Ascierto, Lisa Licitra, Caroline Dutriaux, L. Thomas, Nicolás Meyer, B. Guillot, Reinhard Dummer, Petr Arenberger, Kate Fife, A. Raimundo, Emi Dika, Natalie Dimier, A. Fittipaldo, Ioannis Xynos, Johan Hansson - European Journal of Cancer 2017 cited by 284

  18. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

    Authors: E. Maubec, Marouane Boubaya, Peter Petrow, M. Beylot‐Barry, Nicole Basset‐Séguin, Lydia Deschamps, Jean‐Jacques Grob, Brigitte Dréno, Isabelle Scheer-Senyarich, Coralie Bloch‐Queyrat, M.‐T. Leccia, Andreea Stefan, Philippe Saïag, Florent Grange, Nicolás Meyer, Julie De Quatrebarbes, Monica Dinulescu, Délphine Legoupil, L. Machet, O. Dereure, O. Zehou, Henri Montaudié, E. Wierzbicka-Hainaut, Yannick Le Corre, Sandrine Mansard, Sarah Guégan, Jean‐Philippe Arnault, S. Dalac, F. Aubin, Céline Alloux, Isabelle Lopez, Soufian Cherbal, Annick Tibi, Vincent Lévy, on behalf of Groupe de Cancérologie Cutanée - Journal of Clinical Oncology 2020 cited by 174

  19. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

    Authors: Corine Bertolotto, Fabienne Lesueur, Sandy Giuliano, Thomas Strub, Mahaut de Lichy, Karine Bille, Philippe Dessen, Benoit d’Hayer, Hamida Mohamdi, Audrey Remenieras, E. Maubec, Arnaud de la Fouchardière, Vincent Molinié, P. Vabres, Stéphane Dalle, Nicolas Poulalhon, Tanguy Martin‐Denavit, L. Thomas, Pascale Andry-Benzaquen, N. Dupin, F. Boitier, Annick Rossi, Jean‐Luc Perrot, B. Labeille, Caroline Robert, Bernard Escudier, Olivier Caron, Laurence Brugières, Simon Saule, Betty Gardie, Sophie Gad, Stéphane Richard, Jérôme Couturier, Bin Tean Teh, Paola Ghiorzo, Lorenza Pastorino, Susana Puig, Célia Bádenas, Håkan Olsson, Christian Ingvar, Etienne Rouleau, Rosette Lidereau, Philippe Bahadoran, Philippe Vielh, Eve Corda, Hélène Blanché, Diana Zélénika, Pilar Galán, The French Familial Melanoma Study Group, F. Aubin, Bertrand Bachollet, Céline Becuwe, Pascaline Berthet, Yves Jean Bignon, Valérie Bonadona, Jean‐Louis Bonafé, Marie‐Noëlle Bonnet‐Dupeyron, F. Cambazard, J. Chevrant‐Breton, Isabelle Coupier, S. Dalac, Liliane Demange, M. D’Incan, Catherine Dugast, Laurence Faivre, Lynda Vincent-Fétita, Marion Gauthier-Villars, Brigitte Gilbert, Florent Grange, Jean‐Jacques Grob, Philippe Humbert, Nicolas Janin, Pascal Joly, Delphine Kérob, Christine Lasset, Dominique Leroux, J. Levang, Jean‐Marc Limacher, C. Bulaï Livideanu, Michel Longy, Alain Lortholary, Dominique Stoppa-Lyonnet, Sandrine Mansard, L Mansuy, Karine Marrou, Christine Matéus, Christine Maugard, Nicolás Meyer, Catherine Noguès, P Souteyrand, Laurence Venat‐Bouvet, Hélène Zattara, Valérie Chaudru, Gilbert Lenoir, Mark Lathrop, Irwin Davidson, Marie-Françoise Avril, Florence Démenais, Robert Ballotti, Brigitte Bressac–de Paillerets - Nature 2011 cited by 522

  20. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial

    Authors: Renaud Felten, Valérie Devauchelle‐Pensec, Raphaèle Séror, P. Duffau, David Saadoun, É. Hachulla, Hatron Pierre Yves, Carine Salliot, Aleth Perdriger, Jacques Morel, A. Mékinian, Olivier Vittecoq, Jean‐Marie Berthelot, E. Dernis, Véronique Le Guern, Philippe Dieudé, C. Larroche, Christophe Richez, Thierry Martin, Charles Zarnitsky, Gilles Blaison, P. Kieffer, F. Maurier, Azeddine Dellal, S. Rist, Emmanuel Andrès, A. Contis, Emmanuel Chatelus, Christelle Sordet, Jean Sibilia, Cécile Arnold, Mira Y. Tawk, Ouafaa Aberkane, Lise Holterbach, P. Cacoub, Alain Saraux, Xavier Mariette, Nicolás Meyer, Jacques‐Eric Gottenberg - Annals of the Rheumatic Diseases 2020 cited by 106

  21. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

    Authors: Floriane Gallais, Pierre Gantner, Timothée Bruel, Aurélie Velay, Delphine Planas, Marie-Josée Wendling, Sophie Bayer, Morgane Solis, Elodie Laugel, Nathalie Reix, Anne Schneider, Ludovic Glady, Baptiste Panaget, Nicolas Collongues, Marialuisa Partisani, Jean‐Marc Lessinger, Arnaud Fontanet, David Rey, Yves Hansmann, Laurence Kling-Pillitteri, Olivier Schwartz, J. de Sèze, Nicolás Meyer, Maria Gonzalez, Catherine Schmidt‐Mutter, Samira Fafi‐Kremer - EBioMedicine 2021 cited by 239

  22. High endothelial venules (HEVs) in human melanoma lesions

    Authors: Ludovic Martinet, Sophie Le Guellec, Thomas Filleron, Laurence Lamant, Nicolás Meyer, Philippe Rochaix, Ignacio Garrido, Jean‐Philippe Girard - OncoImmunology 2012 cited by 185

  23. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1

    Authors: Caroline Imbert, Anne Montfort, Marine Fraisse, Elie Marcheteau, Julia Gilhodes, E. Martin, Florie Bertrand, Marlène Marcellin, Odile Burlet‐Schiltz, Anne Gonzalez de Peredo, Virginie Garcia, Stéphane Carpentier, Sophie Tartare‐Deckert, Pierre Brousset, Philippe Rochaix, Florent Puisset, Thomas Filleron, Nicolás Meyer, Laurence Lamant, Thierry Levade, Bruno Ségui, Nathalie Andrieu‐Abadie, Céline Colacios - Nature Communications 2020 cited by 120

  24. COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines/SGLT2 prooxidant pathway

    Authors: Ali Mroueh, Walaa Fakih, Adrien Carmona, Antonin Trimaille, Kensuke Matsushita, Benjamin Marchandot, Abdul Wahid Qureshi, Dal-Seong Gong, Cyril Auger, Laurent Sattler, Antje Reydel, Sébastien Hess, Walid Oulehri, Olivier Vollmer, Jean‐Marc Lessinger, Nicolás Meyer, Michael Paul Pieper, Laurence Jesel, Magnus Bäck, Valérie B. Schini‐Kerth, Olivier Morel - Journal of Thrombosis and Haemostasis 2023 cited by 39